NL-OMON35929已完成不适用
A phase I, single-centre, randomised, single-blinded, placebo-controlled single ascending dose study, followed by an open-label extension, evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of ALX 0651, administered intravenously to healthy male volunteers. - ALX 0651 SAD and open-label extension in healthy male
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Ablynx NV
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Healthy male volunteer
- •- Age between 18-55 years
- •- BMI between 19-29 kg/m2
- •- Only non-smokers
排除标准
- •Suffering from: hepatitis B or C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study or in case of donating more than 1.5 liter of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
1 期
A Phase 1, Safety and Pharmacokinetic Study of CSL312 in Healthy SubjectsHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersInflammatory and Immune System - Other inflammatory or immune system disordersHereditary AngioedemaACTRN12616001438448CSL Limited48
已完成
1 期
Study of first dosing of a new compound DNDi-6148 in healthy volunteers to assess safety and drug levels in blood and urine after escalating single doseTreatment of visceral and/or cutaneous leishmaniasisInfections and InfestationsLeishmaniasisISRCTN54981564Drugs for Neglected Diseases Initiative64
已完成
1 期
A study to investigate the safety, tolerability and activity of multiple ascending doses of DNDI-0690 in healthy volunteers including assessment of heart and kidney functioThe safety, tolerability and fluid exposure of a drug aimed to treat visceral and cutaneous leishmaniasis in healthy volunteersISRCTN30122193Drugs for Neglected Diseases Initiative45
已完成
1 期
A study to assess safety, drug levels in blood and markers of immune system response after an escalating single dose of a new compound developed for the treatment of cutaneous leishmaniasis, CpG-ODN-D35, in healthy male subjectsCutaneous leishmaniasisInfections and InfestationsISRCTN15458851Drugs for Neglected Diseases Initiative54
已完成
1 期
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of ascending multiple oral doses of XW10172 in healthy adult subjectsarcolepsyNarcolepsyInflammatory and Immune System - Autoimmune diseasesNeurological - Other neurological disordersACTRN12618001038280XW Laboratories (Australia) Pty Ltd24